Vischer advised Proteomedix, a Swiss biotech subsidiary of Onconetix, on a licensing agreement with Swedish pancreatic cancer diagnostics company Immunovia. The agreement Under the terms of the agreement, Proteomedix will supply Immunovia with master
Tags :Christian Wyss
Vischer advised Medartis, an SIX-listed orthopedic company with headquarters in Basel specialising in head and extremity surgery, on its acquisition of the remaining 53% of Geneva-based KeriMedical. Pursuant to the deal, Medartis becomes the sole owner
Walder Wyss and Vischer are amongst the firms involved in Granite Bio’s Series A and Series B financing round. In particular Vischer advised Forbion and Sanofi Ventures on all legal issues related to their
EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro Ocampo’s laboratory at the University of Lausanne, has raised EUR 10 million from Prima Materia, an investment
Medartis, a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand
Basel-based orthopedic firm, Medartis, has successfully completed the acquisition of an additional 18% stake in Geneva-based implant manufacturer, KeriMedical, for approximately CHF 18 million. This deal will raise Medartis’ stake to 47%, further cementing the company’s commitment
Resistell, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round
